Research & Development
Oxcia has two on-going clinical phase 1 trials in solid and hematological
cancer investigating the novel and first-in-class MTH1 inhibitor karonudib.
DNA repair pathways as targets for cancer therapy
Genomic instability is a universal hallmark of all cancers. Many of the most prescribed chemotherapeutics target this genomic instability by further damage the DNA, resulting in cell death. However, DNA repair makes cancer cells survive and result in misincorporation of erroneous bases leading to mutations, further driving the cancer. DNA repair is also one of the underlying causes for development of resistance to chemotherapy.
Directly targeting DNA repair is a promising way of treating cancer.